Products RHB-102 + Placebo Oral Tablet
RHB-102 + Placebo Oral Tablet Phase 3 Completed 📈 Rising Gastroenteritis, Gastritis
Dec 8, 2014 → Feb 16, 2017
About RHB-102 + Placebo Oral Tablet RHB-102 + Placebo Oral Tablet is a phase 3 stage product being developed by RedHill Biopharma for Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02246439. Target conditions include Gastroenteritis, Gastritis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02246439 Phase 3 Completed Dec 8, 2014 Feb 16, 2017 Gastroenteritis
Product Company Stage Hype Score Placebo + HIL-214 HilleVax Phase 1 HIL-214 + Placebo HilleVax Phase 2/3 HIL-214 HilleVax Phase 2 HIL-214 + Placebo HilleVax Phase 2/3 Benralizumab + Placebo AstraZeneca Phase 2/3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) Merck Phase 3 Rotavirus Vaccine Merck Pre-clinical Rotavirus Vaccine, Live, Oral, Pentavalent Merck Phase 3 RotaTeq (V260) + IPV Merck Phase 3 V260 + Placebo to V260 + OPV + DTaP Merck Phase 3 Prulifloxacin + Placebo Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 1 RotaTeq™ experimental formulation + RotaTeq™ existing formulation Merck Phase 3 prulifloxacin Merck Phase 3 montelukast Merck Pre-clinical Bacillus Clausii Sanofi Phase 3 Bacillus clausii + Oral Rehydration Therapy Sanofi Approved VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet Vaxart Phase 1 VXA-G1.1-NN Oral Vaccine Vaxart Phase 1
Other Products from RedHill Biopharma